Sowell Financial Services LLC Purchases Shares of 5,262 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Sowell Financial Services LLC acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,262 shares of the specialty pharmaceutical company's stock, valued at approximately $352,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. US Bancorp DE increased its position in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the period. GAMMA Investing LLC grew its holdings in shares of ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after acquiring an additional 881 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $166,000. Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $200,000. Finally, Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $204,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on ANIP shares. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company's stock, valued at $5,526,799.20. The trade was a 0.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock worth $346,854 in the last ninety days. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $0.95 during midday trading on Tuesday, reaching $66.98. 215,811 shares of the company's stock traded hands, compared to its average volume of 312,243. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -52.74 and a beta of 0.55. The stock has a 50 day moving average of $64.57 and a 200 day moving average of $61.43.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. ANI Pharmaceuticals's revenue was up 43.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.82 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.